Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review

SAT0207 Comparison of Efficacies of Abatacept and Tocilizumab in Patients with Rheumatoid Arthritis by a Propensity-Score Matching

(2015) S. Kubo et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

(2015) Jeremy Sokolove et al.   ANNALS OF THE RHEUMATIC DISEASES

Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis

(2015) Luisa Lindenberg et al.   ARTHRITIS RESEARCH & THERAPY

Autoantibodies in Prediction of the Development of Rheumatoid Arthritis Among Healthy Relatives of Patients With the Disease

(2015) Cesar Ramos-Remus et al.   Arthritis & Rheumatology

Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA

(2014) Carolin Hecht et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

(2014) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Anticyclic Citrullinated Protein Antibodies Are Implicated in the Development of Cardiovascular Disease in Rheumatoid Arthritis

(2014) Nuria Barbarroja et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study

(2014) Hubert G Nüßlein et al.   BMC MUSCULOSKELETAL DISORDERS

Periodontal disease and subgingival microbiota as contributors for rheumatoid arthritis pathogenesis

(2014) Jose U. Scher et al.   CURRENT OPINION IN RHEUMATOLOGY

Predictors of Response to TNF Antagonists

(2014) Eva Salgado et al.   CURRENT PHARMACEUTICAL DESIGN

High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis

(2014) Anaïs Gardette et al.   JOINT BONE SPINE

Independent Relationship of Osteoprotegerin Concentrations with Endothelial Activation and Carotid Atherosclerosis in Patients with Severe Rheumatoid Arthritis

(2014) P. H. Dessein et al.   JOURNAL OF RHEUMATOLOGY

A Metaanalysis of the Increased Risk of Rheumatoid Arthritis-related Pulmonary Disease as a Result of Serum Anticitrullinated Protein Antibody Positivity

(2014) J. Zhu et al.   JOURNAL OF RHEUMATOLOGY

Abatacept Reduces Levels of Switched Memory B Cells, Autoantibodies, and Immunoglobulins in Patients with Rheumatoid Arthritis

(2014) M. Scarsi et al.   JOURNAL OF RHEUMATOLOGY

Osteoprotegerin Concentrations Relate Independently to Established Cardiovascular Disease in Rheumatoid Arthritis

(2014) R. Lopez-Mejias et al.   JOURNAL OF RHEUMATOLOGY

Prevalence and predictive value of anti-cyclic citrullinated protein antibodies for future development of rheumatoid arthritis in early undifferentiated arthritis

(2014) Yasser Emad et al.   Modern Rheumatology

Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α

(2014) Sachiko Onishi et al.   Modern Rheumatology

Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index

(2014) Shin-ya Kawashiri et al.   Modern Rheumatology

The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNFα Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-Analysis

(2014) Qianwen Lv et al.   PLoS One

Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study

(2014) C. A. Kelly et al.   RHEUMATOLOGY

Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study

(2014) I. Hafstrom et al.   BMJ Open

Rituximabe para o tratamento da artrite reumatoide: Revisão sistemática

(2014) Lívia Lovato Pires de Lemos et al.   Revista Brasileira De Reumatologia

Rheumatoid Factor as a Potentiator of Anti-Citrullinated Protein Antibody-Mediated Inflammation in Rheumatoid Arthritis

(2014) Jeremy Sokolove et al.   Arthritis & Rheumatology

Systematic Review: Accuracy of Anti–Citrullinated Peptide Antibodies for Diagnosing Rheumatoid Arthritis

(2013) Penny F. Whiting   ANNALS OF INTERNAL MEDICINE

Review on the Influence of Protocol Design on Clinical Outcomes in Rheumatoid Arthritis Treated with Rituximab

(2013) Shawn Shetty et al.   ANNALS OF PHARMACOTHERAPY

Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies

(2013) Arnd Kleyer et al.   ANNALS OF THE RHEUMATIC DISEASES

Multiplex Analyses of Antibodies Against Citrullinated Peptides in Individuals Prior to Development of Rheumatoid Arthritis

(2013) Mikael Brink et al.   ARTHRITIS AND RHEUMATISM

Brief Report: Citrullination Within the Atherosclerotic Plaque: A Potential Target for the Anti-Citrullinated Protein Antibody Response in Rheumatoid Arthritis

(2013) Jeremy Sokolove et al.   ARTHRITIS AND RHEUMATISM

Arthritis and bone loss

(2013) Arnd Kleyer et al.   CURRENT OPINION IN RHEUMATOLOGY

Adaptive immunity in rheumatoid arthritis

(2013) Lars Klareskog et al.   CURRENT OPINION IN RHEUMATOLOGY

Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: Systematic review and meta-analysis of observational studies

(2013) Eva Salgado et al.   JOINT BONE SPINE

Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition

(2013) Khaled Amara et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Longterm Effects of Rituximab on B Cell Counts and Autoantibody Production in Rheumatoid Arthritis: Use of High-sensitivity Flow Cytometry for More Sensitive Assessment of B Cell Depletion

(2013) A. Vancsa et al.   JOURNAL OF RHEUMATOLOGY

Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice

(2013) Yves-Marie Pers et al.   RHEUMATOLOGY

Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis

(2013) R.J. Maneiro et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study

(2013) Nicola Bizzaro et al.   ARTHRITIS RESEARCH & THERAPY

Smoking and overweight determine the likelihood of developing rheumatoid arthritis

(2012) Maria J H de Hair et al.   ANNALS OF THE RHEUMATIC DISEASES

A prediction rule for the development of arthritis in seropositive arthralgia patients

(2012) Lotte Arwen van de Stadt et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

(2012) John D Isaacs et al.   ANNALS OF THE RHEUMATIC DISEASES

Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the ‘AMC-Senshu’ method

(2012) Jing Shi et al.   ANNALS OF THE RHEUMATIC DISEASES

Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry

(2012) J E Gottenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

(2012) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

Cardiovascular Risk in Rheumatoid Arthritis

(2012) Eugenia Gkaliagkousi et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin

(2012) Ulrike Harre et al.   JOURNAL OF CLINICAL INVESTIGATION

The influence of ACPA status and characteristics on the course of RA

(2012) Annemiek Willemze et al.   Nature Reviews Rheumatology

Autoantibody Epitope Spreading in the Pre-Clinical Phase Predicts Progression to Rheumatoid Arthritis

(2012) Jeremy Sokolove et al.   PLoS One

Predictive Factors of Rituximab Response in Rheumatoid Arthritis: Results From a French University Hospital

(2012) M. Couderc et al.   ARTHRITIS CARE & RESEARCH

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

(2011) M. H. Buch et al.   ANNALS OF THE RHEUMATIC DISEASES

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

(2011) K. Chatzidionysiou et al.   ANNALS OF THE RHEUMATIC DISEASES

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes

(2011) J. Bathon et al.   ANNALS OF THE RHEUMATIC DISEASES

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE

(2011) Paul P Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study

(2011) Jérémie Sellam et al.   ARTHRITIS AND RHEUMATISM

Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment

(2011) Preeti Lal et al.   ARTHRITIS AND RHEUMATISM

Immunotherapeutic implication of IL-6 blockade

(2011) Toshio Tanaka et al.   Immunotherapy

Second Generation Automated Anti-CCP Test Better Predicts the Clinical Diagnosis of Rheumatoid Arthritis

(2011) Mohamed Elrefaei et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Are the anti-cyclic citrullinated peptide antibodies independent predictors of myocardial involvement in patients with active rheumatoid arthritis?

(2011) D. Marasovic-Krstulovic et al.   RHEUMATOLOGY

Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis

(2011) Kamal Esalatmanesh et al.   RHEUMATOLOGY INTERNATIONAL

The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years

(2011) Licia Maria Henrique da Mota et al.   RHEUMATOLOGY INTERNATIONAL

Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients

(2011) G Hjeltnes et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis

(2011) Heidi Kokkonen et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

(2010) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity

(2010) T. G. Kormelink et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities

(2010) A. Ioan-Facsinay et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

(2010) P. P. Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: Implications for autoimmunity in rheumatoid arthritis

(2010) Natalia Wegner et al.   ARTHRITIS AND RHEUMATISM

Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion

(2010) Edward M. Vital et al.   ARTHRITIS AND RHEUMATISM

The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis

(2010) Mohammed Z Cader et al.   BMC MUSCULOSKELETAL DISORDERS

Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial

(2010) P. J. MEASE et al.   JOURNAL OF RHEUMATOLOGY

Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan

(2010) Kumi Shidara et al.   RHEUMATOLOGY INTERNATIONAL

Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies

(2010) Tracey M. Farragher et al.   ARTHRITIS CARE & RESEARCH

Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: Two faces of the same coin

(2010) Elena Bartoloni et al.   ARTHRITIS CARE & RESEARCH

The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis

(2010) Maria D Mjaavatten et al.   ARTHRITIS RESEARCH & THERAPY

Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor

(2010) Alejandro Balsa et al.   ARTHRITIS RESEARCH & THERAPY

Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis

(2009) L. Damjanovska et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

(2009) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

(2009) M J L Peters et al.   ANNALS OF THE RHEUMATIC DISEASES

Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis

(2009) Francisco Javier López-Longo et al.   ARTHRITIS AND RHEUMATISM

Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis

(2009) Michael P. M. van der Linden et al.   ARTHRITIS AND RHEUMATISM

Rheumatoid arthritis

(2009) Lars Klareskog et al.   LANCET

Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis

(2009) Raimon Sanmartí et al.   ARTHRITIS RESEARCH & THERAPY

Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study

(2009) Pernille Bøyesen et al.   ARTHRITIS RESEARCH & THERAPY

Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response

(2009) Magda Nakou et al.   ARTHRITIS RESEARCH & THERAPY

Progression of joint damage in early rheumatoid arthritis: Association with HLA–DRB1, rheumatoid factor, and anti–citrullinated protein antibodies in relation to different treatment strategies

(2008) J. K. de Vries-Bouwstra et al.   ARTHRITIS AND RHEUMATISM

Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies

(2008) J. Antonio Aviña-Zubieta et al.   ARTHRITIS AND RHEUMATISM

Atherosclerosis in Autoimmune Rheumatic Diseases—Mechanisms and Clinical Findings

(2008) Hasya Zinger et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

The relationship between anti‐cyclic citrullinated peptide and bone mineral density and radiographic damage in patients with rheumatoid arthritis

(2008) H. Guler et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Carotid Intima-Media Thickness Predicts the Development of Cardiovascular Events in Patients with Rheumatoid Arthritis

(2008) Carlos Gonzalez-Juanatey et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab

(2008) Sanna Rosengren et al.   ARTHRITIS RESEARCH & THERAPY